High Tide Inc. (Nasdaq: HITI), a prominent retail-forward cannabis enterprise, has successfully completed its acquisition of a 51% majority stake in Germany-based Remexian Pharma GmbH for an estimated €26.4 million. This strategic move, finalized on September 2, 2025, signifies High Tide’s definitive entry into Europe’s largest federally regulated cannabis market, establishing a robust platform for future European growth and diversifying its revenue base beyond Canada. This key piece of news in the rapidly evolving global cannabis landscape positions the company for significant expansion.
Strategic Expansion into Europe
High Tide’s acquisition of Remexian Pharma GmbH marks a pivotal moment, allowing the company to plant its flag firmly in the German medical cannabis sector. Germany represents a critical gateway to the European market, which is experiencing strong and trending growth driven by evolving regulations and increasing patient demand. With medical cannabis sales in Germany projected to exceed €670 million in 2025 and reach €1.32 billion by 2029, the strategic importance of establishing a presence here cannot be overstated. High Tide’s move is designed to capitalize on this burgeoning market, leveraging Remexian’s established infrastructure and licensing.
The Deal Unpacked
The acquisition was structured with capital efficiency in mind. High Tide acquired its 51% interest for approximately €26.4 million. The payment was satisfied through a combination of €7.65 million in cash, a €7.65 million loan bearing 7% annual interest, and 5,864,373 High Tide shares valued at €11.1 million. This structure preserves High Tide’s liquidity while securing operational control. The deal also includes a five-year call option for High Tide to acquire the remaining 49% of Remexian, exercisable after 24 months, and a corresponding put option for Remexian’s owners, providing strategic flexibility for future ownership consolidation. The transaction implies an enterprise valuation for Remexian of €53.4 million, based on 3.64 times its annualized Adjusted EBITDA for the six months ending March 31, 2025.
High Tide’s Vision and Remexian’s Capabilities
High Tide, renowned for its extensive Canadian retail footprint with its Canna Cabana subsidiary—the largest cannabis retail chain in Canada and second-largest globally—is now integrating Remexian’s pharmaceutical expertise into its operations. Remexian Pharma GmbH, founded in 2018 and headquartered near Berlin, is a pharmaceutical company focused on the importation and wholesale of medical cannabis. It operates an EU GDP-certified warehouse, implying specialized pharmaceutical equipment and stringent operational standards, and holds licenses to import from 19 countries, including Canada. This diverse import capability, coupled with High Tide’s significant Canadian procurement experience, aims to enhance the share of Canadian medical cannabis imports into Germany. CEO Raj Grover stated that Remexian is an “ideal match,” mirroring High Tide’s commitment to discount pricing and operational approach, thereby creating a stronger foundation for growth and leveraging essential tools for market access.
Market Context and Future Outlook
Germany’s medical cannabis market is characterized by a robust import system, with significant volumes flowing from countries like Canada. Remexian played a notable role, selling 7 tonnes of cannabis flower in Q2 2025, representing 16% of Germany’s total imports for that quarter. High Tide’s strategic foresight recognizes the potential even amidst evolving regulations, such as the ongoing debate around the German telemedicine bill. The company believes the market will continue to grow, reflecting trending demand for cannabis products. By combining Remexian’s distribution network and import licenses with High Tide’s scale and procurement expertise, the company is well-positioned to capitalize on current market trends and solidify its position as a major player. This move is seen as a crucial step in High Tide’s ambition to become a long-term global leader in the cannabis industry.
Conclusion
The successful acquisition of Remexian Pharma GmbH is a landmark event for High Tide, marking its substantial expansion into the critical European cannabis market. This significant news signifies its entry into Europe’s largest federally regulated cannabis market, establishing a robust platform for future European growth. This strategic integration not only diversifies its revenue streams but also leverages synergies between its Canadian success and Remexian’s German market access, providing essential tools for continued expansion. As the European cannabis sector continues its upward trajectory, High Tide appears poised to capture significant opportunities, demonstrating its commitment to global leadership through calculated acquisitions and operational excellence.
